Opening the Black Box of Pharmaceutical Patent Value: An Empirical Analysis
Patents and patent valuation have raised tremendous concerns from the research-based pharmaceutical industry for a long time. Questions about the valuation of drug patent portfolios, the assessment of research and development (R&D) performance or innovation output, and the competitive position of different firms in the industry all tend to revolve around the basic question of phannaceutical patent valuation. This article aims to validate the impact of pharmaceutical technology characteristics on patent value and to optimize classic patent valuation methods in the drug field. We selected 913 patents in the “Orange Book” of the US Food and Drug Administration as the sample, employed established patent value indicators (EPVI) and pharmaceutical technology’ details indicators (PTDI) as key predictors for pharmaceutical patent value (the value of pharmaceutical patents), and further conducted multiple-variable analysis. It was found that PTDI significantly influences pharmaceutical patent value and, more important, enhances the quality of existing valuation methods. Moreover, the marginal effect of individual predictors on patent value is quantitatively measured. For example, new chemical entities and new dosage forms increase the value by 62% and 60%. and orphan drug and pediatric drug classification decrease the value by 7% and 10%, respectively. In addition, the potential commercial applications of this method are briefly explored in view of the eady stage, high-efficiency, and low-cost characteristics of all value predictors in this method.
Key WordsEmpirical analysis Orange Book Patent Pharmaceutical Valuation
Unable to display preview. Download preview PDF.
- 2.Reitzig M. Valuing patents and patent portfolios from a corporate perspective—theoretical considerations, applied needs, and future challenges. In: United Nations, ed. Intellectual Assets: Valuation and Capitalization, New York: United Nations; 2003: 66–82.Google Scholar
- 4.Smith GV, Parr RL. Valuation of Intellectual Property and intangible Assets. 3rd ed. New York: John Wiley; 2000.Google Scholar
- 5.Griliches Z. Patent statistics as economic indicators: a survey. J Econ Lit. 1990;28:1661–1707.Google Scholar
- 6.Orange Book [database online], Rockville. MD: Food and Drug Administration: 2001. Updated January 30, 2007.Google Scholar
- 8.Legal Status Database [database online]. Mu-nich, Germany: International Patent Documentation Center: 2006. Updated November 1, 2007.Google Scholar
- 9.Patent Citations Data File database online). Cambridge. MA: National Bureau of Economic Research: 1999. Updated December 4, 2004.Google Scholar
- 10.The enforcement of intellectual property rights: a survey of the empirical literature. National Bu-reau of Economic Research website. Available at: http://nber15.nber.org/papers/w6296.pdf. Accessed September 7, 2006.
- 16.Carpenter M, Cooper M, Narin F. Linkage be-tween basic research literature and patents. Res Manage. 1980;3:30–35.Google Scholar
- 18.Global Blockbuster Drug Data [database online]. Shanghai. China: Pharmaceutical Digital Library, 2003. Updated December 20, 2006.Google Scholar
- 19.Espina MI. To Renew or Not to Renew: An Empirical Study of Patent Valuation and Maintenance by the United States Pharmaceutical Industry. New York: Rensselaer Polytechnic Institute; 2003.Google Scholar